Evonik, BellaSeno Team Up to Commercialize 3D-Printed Implants
Chemicals company Evonik and BellaSeno, a developer of 3D-printed resorbable soft tissue and bone reconstruction implants, are collaborating on the commercialization of 3D-printed scaffolds for bone regeneration. The bone scaffolds are made with Evonik’s Resomer polymers and are used for large and complex bone defects. Both companies initially began collaborating in 2019 on scaffolds for chest wall and breast reconstruction.
BellaSeno’s custom resorbable bone scaffolds ensure that grafts used to treat bone and soft-tissue defects are placed in the correct anatomical position. The innovation is described by the company as a step-change for the medical procedure. Although tissue autografts are considered the gold standard for tissue regeneration, they sometimes lack stability and cannot be packed in a controlled manner, said BellaSeno. The 3D-printed scaffolds address these limitations.
The Resomer portfolio of bioresorbable polymers for use with implantable medical devices includes formulations for filament- and powder-based 3D printing. “Evonik’s Resomer polymers combine excellent stability and flexibility. These mechanical properties and their degradation profile allow the scaffold to be safely absorbed at a rate that matches the formation of the patient’s own bone,” said Mohit Chhaya, CEO of BellaSeno. “We believe that these novel bone generation implants hold great promise for patients.
BellaSeno is based in Leipzig, Germany, with a subsidiary in Brisbane, Australia.